| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2015: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2014: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
|
|---|
| Outline of Final Research Achievements |
We have first identified negative regulators of small GTPases, Ral, that plays important roles in human tumorigenesis; RalGAP (JBC, 2009) and reported its important role in bladder cancer progression (Oncogene, 2013). We proceeded the investigation in this investigation as follows: (1) We found that Ral and RalGAP play an important role in inflammatory bowel disease and colitis-associated colon cancer formation. (2) We identified Ral-associated kinase and have been analyzing it. (3) We investigated the mechanism of reduced expression of RalGAP in bladder cancer cells and found an involvement of an epigenetic mechanism such as DNA methylation. (4) We have prepared its conditional KO mice in our laboratory. Currently, we are preparing its tissue specific KO mice. (5) We have summarized recent findings of Ral by focusing on RalGAP and published as a review article.
|
